{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:07:51Z","timestamp":1792066071141,"version":"4.4.0"},"reference-count":98,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2023.2705","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:09:53Z","timestamp":1701173393000},"source":"Crossref","is-referenced-by-count":32,"title":["Lenalidomide use in multiple myeloma (Review)"],"prefix":"10.3892","volume":"20","author":[{"given":"Chao-Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ling","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"issue":"1178224219868235","key":"key20240115110712_b1-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1177\/1178224219868235","article-title":"9. Multiple myeloma: An overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"key":"key20240115110712_b2-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: An update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"issue":"m3176","key":"key20240115110712_b3-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"issue":"407","key":"key20240115110712_b4-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: Available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20240115110712_b5-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"key20240115110712_b6-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17474086.2021.1905513","article-title":"Immunomodulators in newly diagnosed multiple myeloma: Current and future concepts","volume":"14","author":"Delforge","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"key20240115110712_b7-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-Induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol Ther"},{"key":"key20240115110712_b8-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/187152011795347487","article-title":"Lenalidomide-current understanding of mechanistic properties","volume":"11","author":"Tageja","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"key20240115110712_b9-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2012.06.008","article-title":"Novel lenalidomide-based combinations for treatment of multiple myeloma","volume":"85","author":"Cives","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240115110712_b10-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/ajh.23234","article-title":"Lenalidomide in multiple myeloma: Current status and future potential","volume":"87","author":"Quach","year":"2012","journal-title":"Am J Hematol"},{"key":"key20240115110712_b11-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"36","key":"key20240115110712_b12-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"key20240115110712_b13-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tranon.2018.10.004","article-title":"Co- Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion","volume":"12","author":"Tawara","year":"2019","journal-title":"Transl Oncol"},{"key":"key20240115110712_b14-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240115110712_b15-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00432-018-2790-6","article-title":"Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment","volume":"145","author":"Zhou","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20240115110712_b16-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3324\/haematol.2017.164632","article-title":"The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling","volume":"102","author":"D\u00edaz","year":"2017","journal-title":"Haematologica"},{"key":"key20240115110712_b17-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00018-011-0895-z","article-title":"Cytochrome c: The Achilles' heel in apoptosis","volume":"69","author":"Kulikov","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"key20240115110712_b18-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/oby.2012.106","article-title":"Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob\/ob obese mice","volume":"20","author":"Li","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"key20240115110712_b19-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.121.000818","article-title":"Caspase-8 regulates the antimyeloma activity of bortezomib and lenalidomide","volume":"379","author":"Zhou","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"861709","key":"key20240115110712_b20-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.861709","article-title":"Caspase-8: Friend or Foe in bortezomib\/lenalidomide-based therapy for myeloma","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"key20240115110712_b21-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/CMR.0000000000000913","article-title":"Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells","volume":"33","author":"Felici","year":"2023","journal-title":"Melanoma Res"},{"issue":"2203","key":"key20240115110712_b22-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082203","article-title":"Targeting NF-\u03baB signaling for multiple myeloma","volume":"12","author":"Wong","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20240115110712_b23-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"IJH39","key":"key20240115110712_b24-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2021-0017","article-title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy","volume":"11","author":"Bou Zerdan","year":"2022","journal-title":"Int J Hematol Oncol"},{"key":"key20240115110712_b25-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbrc.2018.05.035","article-title":"Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1\u03b2\/NF-\u03baB\/RANKL signaling","volume":"501","author":"Qu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"key20240115110712_b26-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"key20240115110712_b27-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2012.09.016","article-title":"Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes","volume":"13","author":"Castelli","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20240115110712_b28-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-) T-cells","volume":"8","author":"Neuber","year":"2017","journal-title":"Oncotarget"},{"key":"key20240115110712_b29-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3324\/haematol.2021.279930","article-title":"The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells","volume":"108","author":"Richardson","year":"2023","journal-title":"Haematologica"},{"key":"key20240115110712_b30-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/187221411797265890","article-title":"Immunomodulatory properties of thalidomide analogs: Pomalidomide and lenalidomide, experimental and therapeutic applications","volume":"5","author":"Bodera","year":"2011","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"key20240115110712_b31-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"key20240115110712_b32-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20240115110712_b33-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"key20240115110712_b34-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00280-012-1966-z","article-title":"Single-dose pharmacokinetics of lenalidomide in healthy volunteers: Dose proportionality, food effect, and racial sensitivity","volume":"70","author":"Chen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240115110712_b35-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00280-014-2438-4","article-title":"No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers","volume":"73","author":"Chen","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240115110712_b36-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bcpt.12081","article-title":"Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men","volume":"113","author":"Chen","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20240115110712_b37-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"key20240115110712_b38-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/cam4.1422","article-title":"Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma","volume":"7","author":"Lund","year":"2018","journal-title":"Cancer Med"},{"key":"key20240115110712_b39-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"key20240115110712_b40-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"219","DOI":"10.12669\/pjms.38.1.4396","article-title":"Effects of lipid based Multiple Micronutrients Supplement on the birth outcome of underweight pre-eclamptic women: A randomized clinical trial","volume":"38","author":"Mohammad","year":"2022","journal-title":"Pak J Med Sci"},{"key":"key20240115110712_b41-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3109\/10428194.2013.847935","article-title":"Bortezomib and lenalidomide as front-line therapy for multiple myeloma","volume":"55","author":"Zou","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"key20240115110712_b42-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20240115110712_b43-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.18295","article-title":"Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: A practical review","volume":"199","author":"McCaughan","year":"2022","journal-title":"Br J Haematol"},{"key":"key20240115110712_b44-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"key20240115110712_b45-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"key20240115110712_b46-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"key20240115110712_b47-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"key":"key20240115110712_b48-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/cas.13550","article-title":"Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"109","author":"Iida","year":"2018","journal-title":"Cancer Sci"},{"key":"key20240115110712_b49-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13231","article-title":"Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I\/II studies","volume":"102","author":"Dimopoulos","year":"2019","journal-title":"Eur J Haematol"},{"key":"key20240115110712_b50-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"key":"key20240115110712_b51-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"key":"key20240115110712_b52-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-21-3420","article-title":"Safety and efficacy of combination maintenance therapy with ixazomib and lenalidomide in patients with posttransplant myeloma","volume":"28","author":"Patel","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20240115110712_b53-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20240115110712_b54-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/ejh.13586","article-title":"Outcomes of ixazomib\/lenalidomide\/dexamethasone for multiple myeloma: A multicenter retrospective analysis","volume":"106","author":"Takakuwa","year":"2021","journal-title":"Eur J Haematol"},{"key":"key20240115110712_b55-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.clml.2021.05.017","article-title":"Daratumumab plus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma","volume":"21","author":"Jakubowiak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20240115110712_b56-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20240115110712_b57-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"key":"key20240115110712_b58-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/blood.2021010744","article-title":"Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results","volume":"138","author":"Roussel","year":"2021","journal-title":"Blood"},{"key":"key20240115110712_b59-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20406207221104584","key":"key20240115110712_b60-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221104584","article-title":"Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed\/refractory multiple myeloma: a multicenter retrospective analysis","volume":"13","author":"Onda","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"4706","key":"key20240115110712_b61-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184706","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma","volume":"13","author":"Baertsch","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"47","key":"key20240115110712_b62-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00645-1","article-title":"Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update","volume":"12","author":"Bazarbachi","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20240115110712_b63-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1634\/theoncologist.2017-0440","article-title":"FDA approval summary: Lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"issue":"51","key":"key20240115110712_b64-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010051","article-title":"Progress on the application of bortezomib and bortezomib-based nanoformulations","volume":"12","author":"Liu","year":"2021","journal-title":"Biomolecules"},{"issue":"23","key":"key20240115110712_b65-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3390\/biom10010023","article-title":"Attenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma","volume":"10","author":"Yang","year":"2019","journal-title":"Biomolecules"},{"issue":"901","key":"key20240115110712_b66-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09980-9","article-title":"Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States","volume":"22","author":"Medhekar","year":"2022","journal-title":"BMC Cancer"},{"key":"key20240115110712_b67-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/blood.2020006298","article-title":"Daratumumab in transplant regimens for myeloma?","volume":"136","author":"Harousseau","year":"2020","journal-title":"Blood"},{"key":"key20240115110712_b68-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"key20240115110712_b69-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"key20240115110712_b70-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"740796","key":"key20240115110712_b71-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: A promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front Oncol"},{"key":"key20240115110712_b72-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20240115110712_b73-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key20240115110712_b74-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1159\/000365534","article-title":"Treatment of multiple myeloma: Thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy","volume":"37","author":"Koeppen","year":"2014","journal-title":"Oncol Res Treat"},{"key":"key20240115110712_b75-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1212\/WNL.0000000000003093","article-title":"Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study","volume":"87","author":"Dalla Torre","year":"2016","journal-title":"Neurology"},{"key":"key20240115110712_b76-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15569527.2013.787086","article-title":"Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects","volume":"33","author":"Patrizi","year":"2014","journal-title":"Cutan Ocul Toxicol"},{"key":"key20240115110712_b77-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.clml.2015.02.008","article-title":"Practical management of lenalidomide-related rash","volume":"15 (Suppl)","author":"Tinsley","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20240115110712_b78-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/0018578717717394","article-title":"highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide","volume":"52","author":"Shanbhag","year":"2017","journal-title":"Hosp Pharm"},{"key":"key20240115110712_b79-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"key20240115110712_b80-MCO-20-1-02705","first-page":"4117","article-title":"Lenalidomide-associated hepatotoxicity-a case report and literature review","volume":"32","author":"Nojkov","year":"2012","journal-title":"Anticancer Res"},{"issue":"3814","key":"key20240115110712_b81-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097758","article-title":"Lenalidomide-induced severe hepatotoxicity","volume":"110","author":"Hussain","year":"2007","journal-title":"Blood"},{"key":"key20240115110712_b82-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"key20240115110712_b83-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"key20240115110712_b84-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"key20240115110712_b85-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key20240115110712_b86-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3960\/jslrt.19034","article-title":"Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy","volume":"60","author":"Kikuchi","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"key20240115110712_b87-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies","volume":"33","author":"Kekre","year":"2019","journal-title":"Blood Rev"},{"key":"key20240115110712_b88-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"key20240115110712_b89-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"key20240115110712_b90-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1517\/14740338.2011.527331","article-title":"Managing the teratogenic risk of thalidomide and lenalidomide: An industry perspective","volume":"10","author":"Bwire","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"key20240115110712_b91-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/s0140-6736(62)91943-8","article-title":"Thalidomide and congenital abnormalities","volume":"1","author":"Somers","year":"1962","journal-title":"Lancet"},{"key":"key20240115110712_b92-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s43441-021-00327-3","article-title":"Implementation of a pregnancy prevention programme (PPP) with a controlled distribution system (CDS) for the generic teratogenic phthalimides thalidomide, lenalidomide and pomalidomide","volume":"55","author":"Mueller","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"key20240115110712_b93-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.reprotox.2022.10.005","article-title":"Embryo-fetal exposure and developmental outcome of lenalidomide following oral administration to pregnant cynomolgus monkeys","volume":"114","author":"Hui","year":"2022","journal-title":"Reprod Toxicol"},{"issue":"19","key":"key20240115110712_b94-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20240115110712_b95-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat Med"},{"issue":"3233","key":"key20240115110712_b96-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"86","key":"key20240115110712_b97-MCO-20-1-02705","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0110-7","article-title":"Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study","volume":"8","author":"Mikhael","year":"2018","journal-title":"Blood Cancer J"},{"key":"key20240115110712_b98-MCO-20-1-02705","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin Pharmacokinet"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T09:07:20Z","timestamp":1705309640000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2023.2705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2023.2705","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"article-number":"7"}}